BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyazaki-Anzai S, Masuda M, Levi M, Keenan AL, Miyazaki M. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One. 2014;9:e108270. [PMID: 25237811 DOI: 10.1371/journal.pone.0108270] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Chiang JYL, Ferrell JM. Bile Acid Metabolism in Liver Pathobiology. Gene Expr. 2018;18:71-87. [PMID: 29325602 DOI: 10.3727/105221618x15156018385515] [Cited by in Crossref: 103] [Cited by in F6Publishing: 58] [Article Influence: 25.8] [Reference Citation Analysis]
2 Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 195-210 [PMID: 29375205 DOI: 10.3748/wjg.v24.i2.195] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
3 Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med 2022;28:51-66. [PMID: 34815180 DOI: 10.1016/j.molmed.2021.10.005] [Reference Citation Analysis]
4 Jia Q, Xie Y, Lu C, Zhang A, Lu Y, Lv S, Zhang J. Endocrine organs of cardiovascular diseases: Gut microbiota. J Cell Mol Med 2019;23:2314-23. [PMID: 30688023 DOI: 10.1111/jcmm.14164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ma J, Li H. The Role of Gut Microbiota in Atherosclerosis and Hypertension. Front Pharmacol 2018;9:1082. [PMID: 30319417 DOI: 10.3389/fphar.2018.01082] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 23.0] [Reference Citation Analysis]
6 Comeglio P, Morelli A, Adorini L, Maggi M, Vignozzi L. Beneficial effects of bile acid receptor agonists in pulmonary disease models. Expert Opin Investig Drugs 2017;26:1215-28. [PMID: 28949776 DOI: 10.1080/13543784.2017.1385760] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
7 Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol Rev 2021;101:683-731. [PMID: 32790577 DOI: 10.1152/physrev.00049.2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
8 Herman-Edelstein M, Weinstein T, Levi M. Bile acid receptors and the kidney. Curr Opin Nephrol Hypertens 2018;27:56-62. [PMID: 29045336 DOI: 10.1097/MNH.0000000000000374] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Tian J, Huang S, Sun S, Ding L, Zhang E, Huang W. Bile acid signaling and bariatric surgery. Liver Res 2017;1:208-13. [PMID: 30034914 DOI: 10.1016/j.livres.2017.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
10 Zhang L, Fu X, Gui T, Wang T, Wang Z, Kullak-Ublick GA, Gai Z. Effects of Farnesiferol B on Ischemia-Reperfusion-Induced Renal Damage, Inflammation, and NF-κB Signaling. Int J Mol Sci 2019;20:E6280. [PMID: 31842453 DOI: 10.3390/ijms20246280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 25.0] [Reference Citation Analysis]
12 Li X, Su C, Jiang Z, Yang Y, Zhang Y, Yang M, Zhang X, Du Y, Zhang J, Wang L, Jiang J, Hong B. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. NPJ Biofilms Microbiomes 2021;7:36. [PMID: 33863898 DOI: 10.1038/s41522-021-00205-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol 2017;14:79-87. [PMID: 27905479 DOI: 10.1038/nrcardio.2016.183] [Cited by in Crossref: 192] [Cited by in F6Publishing: 181] [Article Influence: 32.0] [Reference Citation Analysis]
14 Halkias C, Darby WG, Feltis BN, McIntyre P, Macrides TA, Wright PFA. Marine Bile Natural Products as Agonists of the TGR5 Receptor. J Nat Prod 2021;84:1507-14. [PMID: 33904732 DOI: 10.1021/acs.jnatprod.0c01327] [Reference Citation Analysis]
15 Masuda M, Miyazaki-Anzai S, Keenan AL, Okamura K, Kendrick J, Chonchol M, Offermanns S, Ntambi JM, Kuro-O M, Miyazaki M. Saturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity. J Clin Invest 2015;125:4544-58. [PMID: 26517697 DOI: 10.1172/JCI82871] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
16 Wang XX, Edelstein MH, Gafter U, Qiu L, Luo Y, Dobrinskikh E, Lucia S, Adorini L, D'Agati VD, Levi J, Rosenberg A, Kopp JB, Gius DR, Saleem MA, Levi M. G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. J Am Soc Nephrol 2016;27:1362-78. [PMID: 26424786 DOI: 10.1681/ASN.2014121271] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
17 Kimber C, Zhang S, Johnson C, West RE 3rd, Prokopienko AJ, Mahnken JD, Yu AS, Hoofnagle AN, Ir D, Robertson CE, Miyazaki M, Chonchol M, Jovanovich A, Kestenbaum B, Frank DN, Nolin TD, Stubbs JR. Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. Kidney360 2020;1:1206-16. [PMID: 34322673 DOI: 10.34067/kid.0003942020] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kristek A, Schär MY, Soycan G, Alsharif S, Kuhnle GGC, Walton G, Spencer JPE. The gut microbiota and cardiovascular health benefits: A focus on wholegrain oats. Nutr Bull 2018;43:358-73. [DOI: 10.1111/nbu.12354] [Cited by in Crossref: 11] [Article Influence: 2.8] [Reference Citation Analysis]
19 Shaik FB, Prasad DV, Narala VR. Role of farnesoid X receptor in inflammation and resolution. Inflamm Res. 2015;64:9-20. [PMID: 25376338 DOI: 10.1007/s00011-014-0780-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
20 Pathak P, Liu H, Boehme S, Xie C, Krausz KW, Gonzalez F, Chiang JYL. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem 2017;292:11055-69. [PMID: 28478385 DOI: 10.1074/jbc.M117.784322] [Cited by in Crossref: 97] [Cited by in F6Publishing: 69] [Article Influence: 19.4] [Reference Citation Analysis]
21 Miyata S, Kawashima Y, Sakai M, Matsubayashi M, Motoki K, Miyajima Y, Watanabe Y, Chikamatsu N, Taniguchi T, Tokuyama R. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. Sci Rep 2021;11:9196. [PMID: 33911126 DOI: 10.1038/s41598-021-88493-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Busnelli M, Manzini S, Chiesa G. The Gut Microbiota Affects Host Pathophysiology as an Endocrine Organ: A Focus on Cardiovascular Disease. Nutrients 2019;12:E79. [PMID: 31892152 DOI: 10.3390/nu12010079] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
23 Barone I, Vircillo V, Giordano C, Gelsomino L, Győrffy B, Tarallo R, Rinaldi A, Bruno G, Caruso A, Romeo F, Bonofiglio D, Andò S, Catalano S. Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts. Cancer Letters 2018;437:89-99. [DOI: 10.1016/j.canlet.2018.08.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
24 Zhu J, Dong X, Liu Q, Wu C, Wang Q, Long Z, Li L. Hydrophobic bile acids relax rat detrusor contraction via inhibiting the opening of the Na⁺/Ca²⁺ exchanger. Sci Rep 2016;6:21358. [PMID: 26892434 DOI: 10.1038/srep21358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Levi M. Role of Bile Acid-Regulated Nuclear Receptor FXR and G Protein-Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease). Hypertension 2016;67:1080-4. [PMID: 27045028 DOI: 10.1161/HYPERTENSIONAHA.115.06417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Giordano C, Barone I, Vircillo V, Panza S, Malivindi R, Gelsomino L, Pellegrino M, Rago V, Mauro L, Lanzino M, Panno ML, Bonofiglio D, Catalano S, Andò S. Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy. Sci Rep 2016;6:21782. [PMID: 26899873 DOI: 10.1038/srep21782] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
27 Lazarević S, Đanić M, Goločorbin-Kon S, Al-Salami H, Mikov M. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacol Res 2019;146:104333. [PMID: 31254667 DOI: 10.1016/j.phrs.2019.104333] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
28 Perino A, Schoonjans K. TGR5 and Immunometabolism: Insights from Physiology and Pharmacology. Trends Pharmacol Sci. 2015;36:847-857. [PMID: 26541439 DOI: 10.1016/j.tips.2015.08.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 10.3] [Reference Citation Analysis]
29 Asgharpour A, Kumar D, Sanyal A. Bile acids: emerging role in management of liver diseases. Hepatol Int. 2015;9:527-533. [PMID: 26320013 DOI: 10.1007/s12072-015-9656-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
30 Li J, Li T. Bile acid receptors link nutrient sensing to metabolic regulation. Liver Res 2017;1:17-25. [PMID: 29098111 DOI: 10.1016/j.livres.2017.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Xue J, Allaband C, Zhou D, Poulsen O, Martino C, Jiang L, Tripathi A, Elijah E, Dorrestein PC, Knight R, Zarrinpar A, Haddad GG. Influence of Intermittent Hypoxia/Hypercapnia on Atherosclerosis, Gut Microbiome, and Metabolome. Front Physiol 2021;12:663950. [PMID: 33897472 DOI: 10.3389/fphys.2021.663950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Leonhardt J, Haider RS, Sponholz C, Leonhardt S, Drube J, Spengler K, Mihaylov D, Neugebauer S, Kiehntopf M, Lambert NA, Kortgen A, Bruns T, Tacke F, Hoffmann C, Bauer M, Heller R. Circulating Bile Acids in Liver Failure Activate TGR5 and Induce Monocyte Dysfunction. Cell Mol Gastroenterol Hepatol 2021;12:25-40. [PMID: 33545429 DOI: 10.1016/j.jcmgh.2021.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Liu L, He X, Feng Y. Coronary heart disease and intestinal microbiota. Coron Artery Dis 2019;30:384-9. [PMID: 31276455 DOI: 10.1097/MCA.0000000000000758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fiorucci S, Biagioli M, Baldoni M, Ricci P, Sepe V, Zampella A, Distrutti E. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opin Drug Discov 2021;:1-16. [PMID: 33849361 DOI: 10.1080/17460441.2021.1916465] [Reference Citation Analysis]
35 Chen W, Fitzpatrick J, Sozio SM, Jaar BG, Estrella MM, Riascos-Bernal DF, Wu TT, Qiu Y, Kurland IJ, Dubin RF, Chen Y, Parekh RS, Bushinsky DA, Sibinga NES. Identification of Novel Biomarkers and Pathways for Coronary Artery Calcification in Nondiabetic Patients on Hemodialysis Using Metabolomic Profiling. Kidney360 2021;2:279-89. [PMID: 34723191 DOI: 10.34067/kid.0004422020] [Reference Citation Analysis]
36 Bryniarski MA, Hamarneh F, Yacoub R. The role of chronic kidney disease-associated dysbiosis in cardiovascular disease. Exp Biol Med (Maywood) 2019;244:514-25. [PMID: 30682892 DOI: 10.1177/1535370219826526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
37 Du Y, Li X, Su C, Wang L, Jiang J, Hong B. The human gut microbiome - a new and exciting avenue in cardiovascular drug discovery. Expert Opin Drug Discov 2019;14:1037-52. [PMID: 31315489 DOI: 10.1080/17460441.2019.1638909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Baars A, Oosting A, Knol J, Garssen J, van Bergenhenegouwen J. The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5. Microorganisms 2015;3:641-66. [PMID: 27682110 DOI: 10.3390/microorganisms3040641] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
39 Yu J, Li S, Guo J, Xu Z, Zheng J, Sun X. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis. Cell Death Dis 2020;11:640. [PMID: 32807788 DOI: 10.1038/s41419-020-02819-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
40 Hu YB, Liu XY, Zhan W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des Devel Ther 2018;12:2213-21. [PMID: 30038487 DOI: 10.2147/DDDT.S170518] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
41 Jovanovich A, Isakova T, Stubbs J. Microbiome and Cardiovascular Disease in CKD. Clin J Am Soc Nephrol 2018;13:1598-604. [PMID: 29743160 DOI: 10.2215/CJN.12691117] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
42 Shen H, Ding L, Baig M, Tian J, Wang Y, Huang W. Improving glucose and lipids metabolism: drug development based on bile acid related targets. Cell Stress 2021;5:1-18. [PMID: 33447732 DOI: 10.15698/cst2021.01.239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Duttaroy AK. Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review. Nutrients 2021;13:E144. [PMID: 33401598 DOI: 10.3390/nu13010144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
44 Camilleri M, Gores GJ. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol. 2015;309:G209-G215. [PMID: 26138466 DOI: 10.1152/ajpgi.00121.2015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
45 Chong Nguyen C, Duboc D, Rainteau D, Sokol H, Humbert L, Seksik P, Bellino A, Abdoul H, Bouazza N, Treluyer JM, Saadi M, Wahbi K, Soliman H, Coffin B, Bado A, Le Gall M, Varenne O, Duboc H. Circulating bile acids concentration is predictive of coronary artery disease in human. Sci Rep 2021;11:22661. [PMID: 34811445 DOI: 10.1038/s41598-021-02144-y] [Reference Citation Analysis]
46 Mousa HS, Lleo A, Invernizzi P, Bowlus CL, Gershwin ME. Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother. 2015;16:633-643. [PMID: 25543678 DOI: 10.1517/14656566.2015.998650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
47 Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Front Pharmacol 2018;9:1382. [PMID: 30559664 DOI: 10.3389/fphar.2018.01382] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
48 Battson ML, Lee DM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem 2018;56:1-15. [PMID: 29427903 DOI: 10.1016/j.jnutbio.2017.12.010] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 13.2] [Reference Citation Analysis]
49 Spinelli V, Chávez-talavera O, Tailleux A, Staels B. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors. Current Opinion in Endocrinology & Diabetes and Obesity 2016;23:138-44. [DOI: 10.1097/med.0000000000000235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
50 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterol 2017;8:29-36. [PMID: 28839882 DOI: 10.1136/flgastro-2016-100741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
51 Miyazaki-Anzai S, Masuda M, Kohno S, Levi M, Shiozaki Y, Keenan AL, Miyazaki M. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J Lipid Res 2018;59:1709-13. [PMID: 29976576 DOI: 10.1194/jlr.M087239] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
52 Miyazaki-Anzai S, Masuda M, Shiozaki Y, Keenan AL, Chonchol M, Kremoser C, Miyazaki M. Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation. Kidney360 2021;2:857-68. [PMID: 34423309 DOI: 10.34067/kid.0007502020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Tailleux A, Rouskas K, Pattou F, Staels B. Bariatric surgery, lipoprotein metabolism and cardiovascular risk. Curr Opin Lipidol 2015;26:317-24. [PMID: 26103612 DOI: 10.1097/MOL.0000000000000197] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
54 Jovanovich A, Isakova T, Block G, Stubbs J, Smits G, Chonchol M, Miyazaki M. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. Am J Kidney Dis 2018;71:27-34. [PMID: 28801122 DOI: 10.1053/j.ajkd.2017.06.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
55 Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res. 2016;118:1844-1855. [PMID: 27230645 DOI: 10.1161/circresaha.116.307591] [Cited by in Crossref: 151] [Cited by in F6Publishing: 74] [Article Influence: 30.2] [Reference Citation Analysis]
56 Sepe V, Distrutti E, Fiorucci S, Zampella A. Farnesoid X receptor modulators 2014-present: a patent review. Expert Opinion on Therapeutic Patents 2018;28:351-64. [DOI: 10.1080/13543776.2018.1459569] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
57 Zeng C, Tan H. Gut Microbiota and Heart, Vascular Injury. Adv Exp Med Biol 2020;1238:107-41. [PMID: 32323183 DOI: 10.1007/978-981-15-2385-4_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Strassheim D, Sullivan T, Irwin DC, Gerasimovskaya E, Lahm T, Klemm DJ, Dempsey EC, Stenmark KR, Karoor V. Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases. Cells 2021;10:3347. [PMID: 34943862 DOI: 10.3390/cells10123347] [Reference Citation Analysis]
59 Jadhav K, Xu Y, Li Y, Xu J, Zhu Y, Adorini L, Lee YK, Kasumov T, Yin L, Zhang Y. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab. 2018;9:131-140. [PMID: 29361497 DOI: 10.1016/j.molmet.2018.01.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
60 Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res 2021;82:101094. [PMID: 33636214 DOI: 10.1016/j.plipres.2021.101094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
61 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
62 Wang XX, Luo Y, Wang D, Adorini L, Pruzanski M, Dobrinskikh E, Levi M. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. J Biol Chem 2017;292:12018-24. [PMID: 28596381 DOI: 10.1074/jbc.C117.794982] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
63 Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients 2020;12:E2982. [PMID: 33003455 DOI: 10.3390/nu12102982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
64 Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH, Othman MHD. Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart. Biomolecules 2018;8:E159. [PMID: 30486474 DOI: 10.3390/biom8040159] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
65 Donkers JM, Roscam Abbing RLP, van de Graaf SFJ. Developments in bile salt based therapies: A critical overview. Biochem Pharmacol 2019;161:1-13. [PMID: 30582898 DOI: 10.1016/j.bcp.2018.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]